~~<i id='48D455C6F6'><strike id='48D455C6F6'><tt id='48D455C6F6'><pre id='48D455C6F6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：focus 2025-08-12 06:42:34 - browse：996

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Beware reading your test results before your doctor does

hotspot

focus

RonnieLevinKayanaSzymczakfortheBostonGlobeIt’sknownthatleadinthewatersupplyhasseverehealtheffects,in

WSS

BIO selects John Crowley as new CEO

Being 'nonadherent' patient made me a more empathetic doctor

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Beware reading your test results before your doctor does

Despite FDA concern, risk that CAR

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

explore

Wikipedia

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Beware reading your test results before your doctor does

Cancer drug shortages should be causing more outrage

Canadians with cystic fibrosis outlive Americans by a decade

Activists slam private health insurers over coverage restrictions

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Moonlake's readout produced a cash windfall. Risks remain

Lupron, used to halt puberty in children, may cause lasting health problems

Moonlake's readout produced a cash windfall. Risks remain

Disappointing trial forces Pfizer to pivot on obesity medicine plans

focus

Dexcom's push to bring CGM to type 2 diabetes patients

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Drug cartel violence flares in western Mexico after vigilante leader's killing

Canadians with cystic fibrosis outlive Americans by a decade

Lupron, used to halt puberty in children, may cause lasting health problems

focus

focus

focus

focus